1-8 of 8
radiation-sensitizing agents
Close
Sort by
Journal Articles

Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma Receiving Radioimmunotherapy

Rebecca L. Elstrom, MD, John P. Leonard, MD, Paul Christos, Peter Martin, MD, Daniel Lebovic, MD, Joseph Osborne, Stanley J. Goldsmith, June Greenberg, RN, Richard R. Furman, MD, Jia Ruan, MD, PhD, Ryan Putman, Erica Chapman, Madhu Mazumdar, Kent A. Griffith, Morton Coleman, MD, Mark S. Kaminski, MD
Journal: Blood
Blood (2012) 120 (21): 1636.
https://doi.org/10.1182/blood.V120.21.1636.1636
Published: 2012
Journal Articles

Drug Transporters in Imatinib Resistance: A New Therapeutic Targeted Approach In CML

Raquel Alves, MSc student, Raquel Fonseca, MSc student, Ana Cristina Gonçalves, MSc, PhD student, Vera Alves, BSc, Ana Margarida Abrantes, MSc, PhD student, Filomena Botelho, MD, PhD, Ana Bela Sarmento-Ribeiro, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 5010.
https://doi.org/10.1182/blood.V118.21.5010.5010
Published: 2011
Journal Articles

Phase 1 Study of Radiosensitization Using Bortezomib in Patients with Relapsed Non-Hodgkin's Lymphoma Receiving Radioimmunotherapy,

Rebecca Elstrom, MD, John P. Leonard, MD, Stanley J. Goldsmith, Paul Christos, Peter Martin, Joseph Osborne, Daniel Lebovic, MD, Ramsey Abdallah, CRC, June Greenberg, Richard R. Furman, MD, Jia Ruan, MD, PhD, Kent A. Griffith, Morton Coleman, MD, Mark S. Kaminski, MD
Journal: Blood
Blood (2011) 118 (21): 3712.
https://doi.org/10.1182/blood.V118.21.3712.3712
Published: 2011
Journal Articles

Bortezomib May Be Safely Combined with Y-90 Ibritumomab Tiuxetan In Patients with Relapsed/Refractory Follicular or Transformed Non-Hodgkin Lymphoma: A Phase I Trial of Combined Induction Therapy and Bortezomib Consolidation

Rupali Roy, M.D., Andrew M Evens, DO, MSc, David P. Patton, B.S., Annette Larsen, B.S., R.N., Alfred Rademaker, Ph.D., Jeffrey Cilley, M.D., Stewart Spies, M.D., Daina Variakojis, M.D., Leo I Gordon, M.D., Jane N. Winter, M.D.
Journal: Blood
Blood (2010) 116 (21): 1749.
https://doi.org/10.1182/blood.V116.21.1749.1749
Published: 2010
Journal Articles

Consolidation of Chemotherapy Response in Mantle Cell Lymphoma (MCL) Patients with 90 Y-Ibritumomab Tiuxetan ( 90 Y-Zevalin) Radioimmunotherapy (RIT).

W. Jurczak, A. Giza, D. Krochmalczyk, J. Wegrzyn, A. Hubalewska-Dydejczyk, A. Sowa-Staszczak, W. Knopinska-Posluszny, B. Zdziarska, S. Krycz-Krzemien, P. Boguradzki, L. Poplawska, A. Skotnicki
Journal: Blood
Blood (2005) 106 (11): 2453.
https://doi.org/10.1182/blood.V106.11.2453.2453
Published: 2005
Journal Articles

Synergistic Activity of the Proteasome Inhibitor PS-341 with Non-Myeloablative 153-Sm-EDTMP in a Syngeneic, Orthotopic Model of Multiple Myeloma.

Apollina Goel, PhD, Angela Dispenzieri, MD, Susan M. Geyer, PhD, Suzanne Greiner, Stephen J. Russell, MD, PhD
Journal: Blood
Blood (2005) 106 (11): 3453.
https://doi.org/10.1182/blood.V106.11.3453.3453
Published: 2005
Journal Articles

Thalidomide Sensitizes 32D cl 3 Hematopoietic Progenitor Cells to Ionizing Irradiation.

Emily E. Greenberger, Michael W. Epperly, PhD, Darcy Franicola, Xichen Zhang, Samuel Jacobs, MD, Joel S. Greenberger, MD
Journal: Blood
Blood (2005) 106 (11): 5139.
https://doi.org/10.1182/blood.V106.11.5139.5139
Published: 2005
Journal Articles

PS-341 Induces Selective Radiosensitization of Multiple Myeloma Cells.

Apollina Goel, Ph.D., Angela Dispenzieri, M.D., Philip R. Greipp, M.D., Thomas E. Witzig, M.D., Ruben A. Mesa, M.D., Stephen J. Russell, M.D., Ph.D.
Journal: Blood
Blood (2004) 104 (11): 2478.
https://doi.org/10.1182/blood.V104.11.2478.2478
Published: 2004